The sea anemone Stichodactyla helianthus, which carpets the Caribbean seafloor, may hold the key to eliminating the senescent cells that survive cancer therapy. A collaboration led by Spanish ...

Fannin Partners LLC has been awarded a $300,000 phase I Small Business Innovation Research (SBIR) grant from the National Eye ...

Adenosine deaminase acting on RNA (ADAR) is the enzyme responsible for adenosine-to-inosine (A-to-I) RNA editing, a process ...

Cellbxhealth plc, previously called Angle plc, appointed CEO Peter Collins along with several non-executives to its board as ...

Stoke Therapeutics Inc.’s speeded-up timeline for zorevunersen, the antisense oligonucleotide in development with Biogen Inc.

Disruption of alternative splicing can generate abnormal mRNA variants, producing nonfunctional proteins or triggering ...

Edwards Lifesciences Corp. said it is scrapping plans to acquire Jenavalve Technology Inc. for $945 million after a federal ...

The treatment of Pseudomonas aeruginosa infections is significantly challenged by the pathogen’s diverse resistance ...

After raising AU$29 million (US$19.44 million) in a series A round, Rage Biotech Pty Ltd. is beginning phase I trials of its ...

It was a battle of the companies with drugs for transthyretin-mediated amyloidosis on the first day of the J.P. Morgan 2026 ...

For individuals with major depressive disorder (MDD) that does not respond to pharmacotherapy, recent decisions by the U.S.

Keiferx LLC has entered into a research collaboration and option agreement with Amneal Pharmaceuticals Inc. to support the pre-IND development of KFRX-06, Keiferx’s brain-penetrant preclinical ...